Compound ID | 239
BAS00127538
Class: Cell wall synthesis inhibitor
| Agent Type: | Semisynthetic; Direct acting; |
| Spectrum of activity: | Gram-positive & Gram-negative |
| Mechanism of action: | Cell wall synthesis inhibitor. Lipid II inhibitor |
| Target Pathogen: | Active against Staphylococcus aureus, Escherichia coli, and Acinetobacter baumannii |
| Propensity to select resistant mutants: | Yes |
| Description: | Di-phenyl-tri-methyl indolene pyrylium; defensin Mimetic. |
| Institute where first reported: | University of Maryland Sch. Of Pharmacy, Baltimore, USA |
| Year first mentioned: | 2013 |
| Highest development stage: | Preclinical |
| Development status: | Experimental |
AntibioticDB is supported by GARDP.
If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions
The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.